Minerva Biotechnologies

Focus: Minerva Biotechnologies is a public-stage biotech company focused on cancer therapeutics and stem cell-derived therapies, headquartered in Waltham, MA. The company is early-stage with a single Phase 1 CAR T program in metastatic breast cancer.

Oncology Cell Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Minerva Biotechnologies

AI assessmentNot Hiring

No open roles listed right now. Follow Minerva Biotechnologies to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells

Metastatic Breast Cancer

PHASE_1

Clinical Trials (1)

NCT04020575Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)

Phase 1

Help build intelligence for Minerva Biotechnologies

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage oncology and cell therapy focus positions you at the frontier of CAR T development in solid tumors, a high-unmet-need area
Public company status provides liquidity and stability relative to private biotech, with access to capital markets
Concentrated team (3 active roles) offers potential for outsized impact and close collaboration in a lean organization

Watch Out For

Single clinical program (Phase 1, metastatic breast cancer) creates narrow pipeline risk and limited near-term catalysts
Very early stage with no marketed products or revenue means no commercial validation and high technical/regulatory execution risk
Minimal hiring activity (3 open roles) suggests limited growth trajectory or newly funded entity, reducing career velocity opportunities

Generated by Claude from Minerva Biotechnologies's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.